🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526083-20-00
Authorised Phase I

A research study looking into how a high dose of s.c. semaglutide works with emptying of the stomach in people with excess body weight

2026-526083-20-00 · tracked via the Priya Life Science EU tracker
Sponsor
Novo Nordisk A/S
Sponsor type
Pharmaceutical company
Therapeutic area
Nutritional and Metabolic Diseases
Decision date
07/09/2026
Enrollment target
60
Sites
Austria

Condition studied

Participants with obesity

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526083-20-00 on CTIS ↗ ← All trials in the EU